Dr Jitendra Singh Announces First National Call of ₹2,000 Crore BIRAC–RDI Fund Under ₹1 Lakh Crore RDI Initiative to Boost Biotech Sector

I have sufficient grounded facts. Writing the note now.

Dr Jitendra Singh: ₹2,000 Crore BIRAC–RDI Fund — UPSC Study Note

1. At a Glance

2. Why in the News

3. Background & Evolution

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic - Designed to crowd-in private R&D, where India spends only ~0.65% of GDP on R&D vs. global leaders >2%. - Bioeconomy scale-up from $165.7 bn to $300 bn in six years implies near-doubling of biotech output [S1].

Scientific / Technological - Funds high-risk, high-impact biotech innovations: biopharma, biomanufacturing, bio-agri, bio-industrial, bio-IT under the BioE3 Policy framework. - Bridges the "valley of death" between TRL-4 prototypes and commercialisation [S1].

Administrative / Governance - Two-tier architecture: ANRF (apex)SLFMs (TDB, BIRAC) → end beneficiaries; reduces ministerial bottlenecks [S2]. - BIRAC's prior incubator network provides ready last-mile delivery [S1].

Strategic - Reduces import dependence in vaccines, biologics, enzymes; complements Atmanirbhar Bharat in sunrise sectors. - Positions India as a global bioeconomy hub alongside USA, EU, China.

6. Recent Developments (last 12–18 months)

7. Prelims Hooks

8. Mains Relevance

9. Related Topics to Study Next

10. Common Errors / Trap Areas

11. Sources